CERO Therapeutics Holdings, Inc. announced on June 23, 2025, that the first patient in its Phase 1 clinical trial of lead compound CER-1236 has completed the initial evaluation. Following review by the trial’s Dose Escalation Safety Committee, preliminary results showed no dose-limiting toxicity (DLT) in the patient.
This positive safety outcome was observed during the planned 28-day observation period after the successful manufacturing of CER-1236 from an AML patient. The absence of DLTs is a significant early indicator for CER-1236, which is a first-in-class biologic targeting a previously unexplored pathway.
The company anticipates dosing the second patient in the cohort shortly, with a second AML patient already identified and having provided informed consent. CERO Therapeutics remains focused on methodically progressing through each phase of this trial and is preparing to initiate its second trial of CER-1236 in solid tumors later this year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.